Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 22,018 matching trials from the local directory fallback.

Filters: Recruiting Clear all

Conditions: Advanced/Metastatic Solid Tumors
Interventions: ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab), Standard of care (Fruquintinib); Drug
Lead sponsor: Adagene Inc; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Scottsdale, Arizona • Duarte, California • Irvine, California + 4 more

Conditions: Healthy
Interventions: Ketamine, Placebo, Ts-134 or XT; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Aging
Interventions: Heat therapy, Thermoneutral water immersion; Other
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 40 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Basal Cell Carcinoma
Interventions: 5% Imiquimod cream, Placebo Vehicle Control Cream; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 1,630 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Long Beach, California • San Diego, California • Bay Pines, Florida + 5 more

Conditions: Ependymoma, Glioblastoma, Medulloblastoma, Primary Brain Tumor
Interventions: Cyclophosphamide, Etoposide, Ibrutinib, Indoximod, Temozolomide; Drug
Lead sponsor: Theodore S. Johnson; Other
Eligibility: 3 Years to 25 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Myeloma Multiple
Interventions: Belantamab mafodotin, Lenalidomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cholesterol; Lipidosis
Interventions: Rosuvastatin 10mg; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 8 Years to 21 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Depression, Trauma, Psychological
Interventions: Not listed
Lead sponsor: Mclean Hospital; Other
Eligibility: 20 Years to 32 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions: Acalabrutinib, Lenalidomide, Rituximab; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: ALS, Alzheimer's Disease, Dementia, Mild Cognitive Impairment, Parkinson's Disease
Interventions: 11C-MC1, 11C-PS13, 18f-florbetaben; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 184 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tuberculosis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Maternal Neoplasia
Interventions: NIPT; Device
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glioblastoma
Interventions: ADI-PEG 20, AZD1390, Lomustine, Paxalisib, Radiation, Regorafenib, Temozolomide, Tinostamustine, Troriluzole, VAL-083, VT1021; Biological · Drug · Radiation
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years and older
Enrollment: 2,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 42
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more

Conditions: Cushing Disease
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 2 Years to 90 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2040
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hodgkin Lymphoma
Interventions: Nivolumab, Ruxolitinib; Drug
Lead sponsor: Veronika Bachanova; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 6
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 3 more

Conditions: Ascending Aorta Aneurysm, Ascending Aortic Aneurysm Enlargement
Interventions: Thoracic Aortic Surgery; Procedure
Lead sponsor: Ottawa Heart Institute Research Corporation; Other
Eligibility: 18 Years to 79 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2035
U.S. locations: 16
States / cities: San Francisco, California • Iowa City, Iowa • Boston, Massachusetts + 12 more

Conditions: Advanced/Metastatic Solid Tumors, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, HNSCC, Head and Neck Squamous Cell Carcinoma, NSCLC
Interventions: MCLA-158, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX, MCLA-158 + Pembrolizumab; Drug · Combination Product
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 31
States / cities: La Jolla, California • Los Angeles, California • San Diego, California + 25 more

Conditions: Hypo-Plastic Myelodysplastic Syndrome (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH), Severe Aplastic Anemia (SAA)
Interventions: Cyclophosphamide, Peripheral Blood Stem Cells; Drug · Other
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 4 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Fatty Liver, Obesity
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 1 Day to 99 Years
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2041
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Neoplasms
Interventions: Gene-modified (GM) T cell therapy; Genetic
Lead sponsor: Celgene; Industry
Eligibility: Not listed
Enrollment: 1,541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2043
U.S. locations: 104
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more

Conditions: Primary Immunodeficiency Disorders
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 90 Years
Enrollment: 1,190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2040
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Cytarabine, Filgrastim, Fludarabine, Idarubicin, Pegfilgrastim, Venetoclax; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atopy, Autoimmunity, Autoinflammation, Primary Immunodeficiency
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 100 Years
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2042
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Crohn's Disease
Interventions: Ustekinumab, Vorinostat; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2035
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Glutamatergic Mechanisms: Aim2

Passive Heat Therapy for Lowering Systolic Blood Pressure and Improving Vascular Function in Mid-life and Older Adults

Basal Cell Carcinoma Chemoprevention Trial

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Liver Adiposity Effects on Pediatric Statin

Early Life Stress and Depression: Molecular and Functional Imaging

Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

Paradoxical Tuberculosis Reactions in Patients Without HIV Infection

IDENTIFY Study: Natural History of Maternal Neoplasia

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Long-Term Follow-Up of Survivors of Pediatric Cushing Disease

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

Early Tracking of Childhood Health Determinants (ETCHED) Study

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

The Mechanistic Biology of Primary Immunodeficiency Disorders

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

NIAID Centralized Sequencing Protocol

An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab